La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Atomo Diagnostics Résultats passés
Nous sommes encore en train de traiter le dernier rapport sur les résultats de cette entreprise.
Passé contrôle des critères 0/6
Atomo Diagnostics's earnings have been declining at an average annual rate of -6.9%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 24.6% per year.
Informations clés
-6.9%
Taux de croissance des bénéfices
10.6%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie | 5.8% |
Taux de croissance des recettes | -24.6% |
Rendement des fonds propres | -53.8% |
Marge nette | -237.0% |
Prochaine mise à jour des résultats | 30 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Jul 05We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Oct 10Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?
Jun 10We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn
Dec 06Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 01We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow
Jul 19Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)
Feb 26Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business
Jan 22Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like
Dec 18When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?
Jul 16Ventilation des recettes et des dépenses
Comment Atomo Diagnostics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 3 | -7 | 6 | 0 |
30 Sep 23 | 3 | -9 | 6 | 0 |
30 Jun 23 | 3 | -10 | 7 | 1 |
31 Mar 23 | 5 | -9 | 7 | 1 |
31 Dec 22 | 8 | -9 | 7 | 1 |
30 Sep 22 | 10 | -7 | 7 | 1 |
30 Jun 22 | 12 | -6 | 7 | 1 |
31 Mar 22 | 10 | -6 | 7 | 1 |
31 Dec 21 | 7 | -6 | 7 | 1 |
30 Sep 21 | 7 | -6 | 7 | 1 |
30 Jun 21 | 7 | -6 | 6 | 1 |
31 Mar 21 | 8 | -8 | 6 | 1 |
31 Dec 20 | 9 | -10 | 6 | 1 |
30 Sep 20 | 7 | -9 | 5 | 1 |
30 Jun 20 | 5 | -9 | 4 | 1 |
31 Mar 20 | 3 | -7 | 4 | 1 |
31 Dec 19 | 1 | -5 | 3 | 1 |
30 Sep 19 | 1 | -5 | 3 | 1 |
30 Jun 19 | 1 | -5 | 3 | 1 |
30 Jun 18 | 0 | -5 | 2 | 3 |
30 Jun 17 | 0 | -5 | 2 | 3 |
Des revenus de qualité: AT1 is currently unprofitable.
Augmentation de la marge bénéficiaire: AT1 is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AT1 is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accélération de la croissance: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Rendement des fonds propres
ROE élevé: AT1 has a negative Return on Equity (-53.75%), as it is currently unprofitable.